Ascentage Pharma trustee buys 200,000 plan shares

The trustee’s total on-market purchases for the scheme stood at 3,115,000 shares; it will not exercise voting rights attached to shares held on trust.

Rhea-AI Filing Summary

Ascentage Pharma Group International said the trustee purchased 200,000 existing shares on-market on October 22, 2026, for the 2022 RSU Scheme to satisfy RSUs upon vesting. Total consideration was HK$5,740,622, excluding related expenses, transaction levy, brokerage, tax, duties and levies; average consideration was approximately HK$28.70 per share. The trustee’s total on-market purchases for the scheme stood at 3,115,000 shares immediately after this purchase.

Filing Explained

The purchased shares are currently held by the trustee under the RSU scheme, and the trustee may not exercise their voting rights.

Key Figures

Purchased Shares: 200,000 shares Total consideration: HK$5,740,622 Average consideration: Approximately HK$28.70 per Purchased Share +2 more

5 metrics

Purchased Shares 200,000 shares Purchased on-market on October 22, 2026 for the 2022 RSU Scheme.

Total consideration HK$5,740,622 For the October 22, 2026 purchase, excluding related expenses, transaction levy, brokerage, tax, duties and levies.

Average consideration Approximately HK$28.70 per Purchased Share For the October 22, 2026 purchase, excluding related expenses, transaction levy, brokerage, tax, duties and levies.

Percentage of total issued Shares Approximately 0.05% Percentage represented by the Purchased Shares as at October 22, 2026.

Total existing Shares purchased by the Trustee 3,115,000 shares On-market for the 2022 RSU Scheme immediately after the October 22, 2026 purchase.

Key Terms

RSUs, on-market, trust deed, vesting

4 terms

RSUs financial

"to satisfy the RSUs upon vesting"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

on-market financial

"purchased by the Trustee on-market for the purpose"

On-market describes buying or selling shares directly through a public stock exchange at the current market price, rather than by a private or negotiated deal. Like buying an item from a store at the posted price instead of haggling privately, on-market trades happen quickly, are visible to other investors, and can move the stock price, so they affect liquidity and provide a transparent signal about supply and demand.

trust deed technical

"terms of the trust deed entered into between the Company and the Trustee"

A trust deed is a legal document used to secure a loan with real property: the borrower transfers title to a neutral third-party trustee to hold as collateral until the loan is repaid. It works like handing the house keys to a trusted friend while you pay back the debt, allowing the lender quicker recovery if the borrower defaults. Investors care because a trust deed determines the lender’s priority, speed of foreclosure, and likelihood of recovering funds in a default.

vesting financial

"to satisfy the RSUs upon vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AAPG shares did the trustee buy for the 2022 RSU Scheme?

The trustee purchased 200,000 existing shares on-market on October 22, 2026, for the 2022 RSU Scheme. The purchased shares represented approximately 0.05% of total issued shares as at the announcement date.

How much did the AAPG trustee pay for the shares?

The total consideration was HK$5,740,622, and average consideration was approximately HK$28.70 per share. Both figures exclude related expenses, transaction levy, brokerage, tax, duties and levies.

Can the trustee vote AAPG shares held for the 2022 RSU Scheme?

The trustee shall not exercise the voting rights attached to shares held on trust under the scheme.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/22/2026 - 04:44 PM EDT Accepted by SEC EDGAR 10/22/2026 - 04:44 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

On October 22, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) posted an announcement on the Hong Kong Stock Exchange entitled, “PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME” . A copy of the announcement is furnished as Exhibit 99.1 to this Report.

1

INDEX TO EXHIBITS

Exhibit Number		Exhibit Title
99.1		Announcement dated October 22, 2026

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: October 22, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

3

Exhibit 99.1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

VOLUNTARY ANNOUNCEMENT

PURCHASE OF SHARES BY THE TRUSTEE

FOR THE PURPOSE OF THE 2022 RSU SCHEME

This announcement is made by Ascentage Pharma Group International (the “Company”) on a voluntary basis. Reference is made to the announcements of the Company dated June 23, 2022, July 14, 2022, October 21, 2022, October 25, 2022, October 26, 2022, October 27, 2022, October 28, 2022, October 31, 2022, May 8, 2023, November 13, 2023, November 14, 2023, November 16, 2023, February 2, 2024, September 2, 2024, October 24, 2024, March 31, 2025, April 8, 2025, April 30, 2025, June 27, 2025, November 27, 2025, December 30, 2025, April 20, 2026, April 30, 2026, May 27, 2026, May 28, 2026, June 10, 2026, June 11, 2026, June 29, 2026, July 13, 2026, September 17, 2026, September 28, 2026 and October 15, 2026 (the “Announcements”) in relation to, among other things, (i) the adoption of and amendments to the 2022 RSU Scheme; (ii) the initial grant and the further grants of the 2022 Awards thereunder; and (iii) the purchase of existing Shares by the Trustee on-market for the purpose of the 2022 RSU Scheme. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

On October 22, 2026, the Trustee purchased a total of 200,000 existing Shares (the “Purchased Shares”) on-market for the purpose of the 2022 RSU Scheme to satisfy the RSUs upon vesting. Details of the Purchased Shares and the latest information about the Shares held by the Trustee under the Scheme are as follows:

Purchase date	:	October 22, 2026
Total number of the Purchased Shares	:	200,000 Shares
Percentage of the Purchased Shares to the total number of issued Shares as at the date of this announcement	:	Approximately 0.05%
Total consideration paid for the Purchased Shares (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	HK$5,740,622
Average consideration per Purchased Share (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	Approximately HK$28.70
Total number of existing Shares purchased by the Trustee on-market for the purpose of the 2022 RSU Scheme immediately after the aforesaid purchases	:	3,115,000 Shares

The Purchased Shares are currently held by the Trustee in accordance with the 2022 RSU Scheme Rules and the terms of the trust deed entered into between the Company and the Trustee. The Trustee shall not exercise the voting rights attached to the Shares held on trust by it. As at the date of this announcement, no further grant of Awards has been made pursuant to the 2022 RSU Scheme apart from the initial grant of the 2022 Awards on June 23, 2022 and the further grants of the 2022 Awards on May 4, 2023, September 2, 2024, June 27, 2025, November 26, 2025, April

20, 2026 and June 29, 2026 as disclosed in the Announcements.

By Order of the Board

Ascentage Pharma Group International
Dr. Yang Dajun

Chairman and Executive Director

Suzhou, People’s Republic of China, October 22, 2026

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong ^{Note 1} as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky ^{Note 2}, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.

Notes:

1. Dr. Lu Simon Dazhong satisfies the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements.

2. Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 ANNOUNCEMENT DATED OCTOBER 22, 2026 11.8 KB